Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients

References

• Karchmer AW, Samore MH, Hadley S, . Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc 1995; 106: 38–47.
   PubMedGoogle Scholar
• Hadley S, Samore MH, Lewis WD, . Major infectious complications after orthotopic liver transplant and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851–859.
   PubMed Web of Science ®Google Scholar
• Grossi PA.Clinical aspects of invasive candidiasis in solid organ transplant recipients. Drugs 2009; 69(Suppl. 1): 15–20.
   Google Scholar
• Singh N, Wagener MM, Marino IR, Gayowski T.Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practice. Transplantation 2002; 73: 63–67.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR, . Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101–1111.
   PubMed Web of Science ®Google Scholar
• Silveira FP, Husain S.Fungal infections in solid organ transplantation. Med Mycol 2007; 45: 305–320.
   PubMed Web of Science ®Google Scholar
• Shi SH, Lu WA, Shen Y, . Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation. Chin Med 2008; 121: 625–630.
   Google Scholar
• Gabardi S Kubiak DW, Chandraker AK, Tullius SG.Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transplant Int 2007; 20: 993–1015.
   PubMed Web of Science ®Google Scholar
• Singh N.Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000; 31: 545–553.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Inf Dis 2009; 48: 503–535.
   PubMed Web of Science ®Google Scholar
• Biancofiore G, Bindi ML, Baldassarri R, . Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transplant Int 2002; 15: 341–347.
   PubMed Web of Science ®Google Scholar
• Eschenauer GA, Lam SW, Carver PL.Antifungal prophylaxis in liver transplant recipients. Liver Transpl 2009; 15: 842–858.
   PubMed Web of Science ®Google Scholar
• Patel R, Portela D, Badley AD, . Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62: 926–934.
   PubMed Web of Science ®Google Scholar
• Collins LA, Samore MH, Roberts MS, . Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644–652.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Malena M, . Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12: 850–858.
   PubMed Web of Science ®Google Scholar
• Hadley S, Huckabee C, Pappas PG, . Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11: 40–48.
   PubMed Web of Science ®Google Scholar
• Playford EG, Webster AC, Sorell TC, Craig JC.Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004; 3: CD004291.
   Google Scholar
• Saliba F.Antifungals and renal safety – getting the balance right. Int J Antimicrob Agents 2006; 27(Suppl. 1):21–24.
   Google Scholar
• Veerareddy PR, Vobalaboina V.Lipid-based formulations of amphotericin B. Drugs Today 2004; 40: 133–145.
   PubMed Web of Science ®Google Scholar
• Hellinger WC, Bonatti H, Yao JD, . Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005; 11: 656–662.
   Google Scholar
• Tollemar J, Höcherstedt K, Ericzon BG, Jalanko H, Ringdün O.Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995; 59: 45–50.
   PubMed Web of Science ®Google Scholar
• Shah T, Lai WK, Gow P, Leeming J, Mutimer D.Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis 2005; 7: 126–132.
   PubMed Web of Science ®Google Scholar
• Singhal S, Ellis RW, Jones SG, . Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 2000; 6: 588–595.
   PubMed Web of Science ®Google Scholar
• Castroagudin JF, Pontón C, Bustamante M, . Prospective interventional study to evaluate the efficacy and safety of lipsomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 2005; 37: 3965–3967.
   PubMedGoogle Scholar
• Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR.Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71: 910–913.
   PubMedGoogle Scholar
• Fortûn J, Martin-Davila P, Moreno S, . Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813–819.
   PubMed Web of Science ®Google Scholar